GSEP
OCUL icon

Golden State Equity Partners’s Ocular Therapeutix OCUL Stock Holding History

Golden State Equity Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,250
Closed -$28.3K – 727
2024
Q3 		$28.3K Buy
+3,250
New +$26.8K 0.01% 469
2022
Q1 		$259K Buy
52,250
+100
+0.2% +$554 0.13% 158
2021
Q4 		$363K Buy
52,150
+19,890
+62% +$154K 0.18% 110
2021
Q3 		$323K Buy
32,260
+18,860
+141% +$212K 0.13% 155
2021
Q2 		$190K Buy
+13,400
New +$204K 0.07% 230

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Golden State Equity Partners's OCUL Position: Q4 2024 in Review

Golden State Equity Partners sold out of Ocular Therapeutix (OCUL) in Q4 2024, closing a stake of 3,250 shares — an estimated $28.3K sold.

Golden State Equity Partners first reported a position in OCUL in Q2 2021 and held it in 5 quarters. The position peaked at $363K in Q4 2021. 179 funds tracked by Wall St. Rank hold OCUL as of Q4 2024.

  • Golden State Equity Partners reported no remaining Ocular Therapeutix position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 3,250 Ocular Therapeutix shares in Q4 2024, an estimated $28.3K.
  • Golden State Equity Partners first reported a position in Ocular Therapeutix in Q2 2021 and held it in 5 quarters.
  • Golden State Equity Partners's Ocular Therapeutix position peaked at $363K in Q4 2021.
  • 179 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.